id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-5625-0002,FDA,FDA-2017-D-5625,Recommendations for Dual 510(k) and CLIA Waiver by Application Studies Draft Guidance for Industry and Food and Drug Administration Staff DRAFT GUIDANCE,Other,Guidance,2017-11-29T05:00:00Z,2017,11,2017-11-29T05:00:00Z,2018-03-31T03:59:59Z,2024-11-07T01:12:24Z,,1,0,0900006482cbce95
FDA-2017-D-5625-0001,FDA,FDA-2017-D-5625,"Recommendations for Dual 510(k) and Clinical Laboratory Improvement
Amendments Waiver by Application Studies; Draft Guidance for Industry
and Food and Drug Administration Staff; Availability",Notice,Notice of Availability,2017-11-29T05:00:00Z,2017,11,2017-11-29T05:00:00Z,2018-01-30T04:59:59Z,2018-01-14T03:27:10Z,2017-25774,0,0,0900006482cbbd24